Why the study?
Myocardial injury causes impaired cardiac function and heart failure, prompting investigation into biocompatible, target-specific exosomes as therapeutic drug delivery systems.
Exosomes offer a promising, highly biocompatible cell-free therapy and drug delivery system for repairing myocardial injury, though significant methodological and delivery challenges remain before clinical application.
Answers are grounded in this paper and cite their sources.
Exosome therapy for myocardial injury remains investigational; leaves open the need for randomized trials before clinical adoption.
Cardiovascular disease has become a major cause of death worldwide. Myocardial injury (MI) caused by myocardial infarction, myocarditis, and drug overdose can lead to impaired cardiac function, culminating in serious consequences such as angina pectoris, arrhythmias, and heart failure. Exosomes exhibit high biocompatibility and target specificity, rendering them an important non-cellular therapy for improving MI. Exosomes are diminutive vesicles that encapsulate nucleic acids and proteins. Exosomes derived from cardiac stem cells themselves have therapeutic effects, and they can also serve as carriers to deliver therapeutic drugs to recipient cells, thereby exerting a therapeutic effect. The molecules within exosomes are encapsulated in a lipid bilayer, allowing them to stably exist in body fluids without being affected by nucleases. Therefore, the utilization of exosomes as drug delivery systems (DDS) for disease treatment has been extensively investigated and is currently undergoing clinical trials. This review summarizes the therapeutic effects of exosomes on MI and provides an overview of current research progress on their use as DDS in MI.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: